California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
IRVINE, Calif., April 19, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO). Investors who purchased or otherwise acquired shares between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 13, 2017 lead plaintiff motion deadline.
If you purchased shares of Lion during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint states that throughout the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that Lion, through its former CEO Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times. When this news was released, shares of Lion declined in value.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
